Arcus Biosciences, Inc. (NYSE:RCUS) was highlighted by Jim Cramer as a speculative stock. The company is a clinical-stage biopharmaceutical company developing cancer therapies. Arcus Biosciences reported revenue of $160 million, up over 310% year-over-year, with cash and securities totaling $927 million. Cramer advised caution due to the company’s financial situation.

While Arcus Biosciences (RCUS) shows potential, other AI stocks may offer better returns with lower risks. Investors seeking undervalued AI stocks can explore options beyond RCUS. For insights on a promising short-term AI stock, a free report is available. Stay informed on stock trends and hidden opportunities in the market.

Read more at Yahoo Finance: “Let This Be Your Speculation”